$BLISSGVS

Bliss GVS Pharma are likely to remain in focus on June 3 after the company announced that it has received an Inspection Closure Report from the World Health Organization (WHO), Geneva, for its manufacturing facility in Palghar, Maharashtra. The report confirmed that the facility complies with the Good Manufacturing Practices (GMP) standards prescribed by the WHO, reinforcing the company's commitment to global quality and manufacturing excellence. In the previous trading session, Bliss GVS Pharma shares ended at Rs 434.75, gaining Rs 32.75 or 8.15 percent. The stock touched a 52-week high of Rs 442.20 on June 2, 2026, and a 52-week low of Rs 118.35 on November 10, 2025. At the current market price, the stock is trading 1.68 percent below its 52-week high and has surged 267.34 percent from its 52-week low.